Eurofins E&E (Electrical and Electronics) is pleased to announce the acquisition of TA Technology (Shanghai) Co., Ltd.

The acquisition of TA Technology (Shanghai) Co., Ltd. ("TA") further broadens the scope, capabilities, and services available from Eurofins E&E in China and across Asia. It is another milestone in the expansion of wireless testing services available from the global network of Eurofins E&E laboratories.

TA provides a wide range of services, focusing on telecommunications and information technology products with wireless capabilities, including a Wi-Fi Alliance Authorised Laboratory, a Bluetooth Qualification Test Facility (BQTF), a GCF RTO, and a CITA-authorized OTA laboratory for cellular testing. Alongside these, TA delivers EMC, RF, SAR, Safety, Interoperability testing and Global Market Access services.

The acquisition of TA follows the recent regional acquisitions of ATL of Taiwan and KCTL of Korea. Further, it demonstrates the commitment of Eurofins E&E to supporting international clients worldwide in their product compliance journey, complemented by the extensive network of E&E labs in North America, Europe and Asia.

About TA Technology (Shanghai) Co., Ltd.

Based in Shanghai with locations in Shenzhen, TA Technology (Shanghai) Co., Ltd. was founded in 2002 with the approval of the Shanghai Municipal People’s Government. TA provides an extensive range of third-party testing and product evaluation services for a wide range of customers.

Accredited by CNAS and A2LA to ISO 17025, TA delivers the highest level of service, both in terms of technical capability and customer support.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing, and in discovery pharmacology, forensics, advanced material sciences and agroscience Contract Research services. Eurofins is also a market leader in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in BioPharma Contract Development and Manufacturing. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 61,000 staff across a network of 900 laboratories in 61 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.